HC Wainwright Estimates BioAtla FY2024 Earnings

BioAtla, Inc. (NASDAQ:BCAB) – Equities research analysts at HC Wainwright issued their FY2024 earnings estimates for BioAtla in a report issued on Wednesday, November 13th. HC Wainwright analyst A. He anticipates that the company will earn ($1.46) per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for BioAtla’s Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The company had revenue of $11.00 million for the quarter. During the same period in the previous year, the business posted ($0.70) EPS.

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of BioAtla in a research note on Monday, September 16th.

BioAtla Stock Performance

BCAB opened at $1.56 on Friday. The firm’s fifty day moving average is $1.91 and its 200 day moving average is $1.87. The stock has a market cap of $75.40 million, a price-to-earnings ratio of -0.92 and a beta of 1.03. BioAtla has a fifty-two week low of $1.14 and a fifty-two week high of $4.02.

Institutional Investors Weigh In On BioAtla

Several large investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in shares of BioAtla during the second quarter valued at approximately $872,000. Scion Asset Management LLC bought a new position in shares of BioAtla during the 2nd quarter worth $869,000. GSA Capital Partners LLP bought a new position in BioAtla in the third quarter worth about $623,000. Bank of Montreal Can boosted its holdings in shares of BioAtla by 55.1% in the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock valued at $554,000 after buying an additional 143,521 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of BioAtla by 28.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company’s stock worth $458,000 after buying an additional 73,598 shares during the last quarter. 77.23% of the stock is owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.